Deramiocel, an investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), met its primary and secondary endpoints in the phase 3 HOPE-3 trial, according to Capricor Therapeutics.
Deramiocel, an investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), met its primary and secondary endpoints in the phase 3 HOPE-3 trial, according to Capricor Therapeutics.
Deramiocel, an investigational...